The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...

NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...

R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.

The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.

The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

The firm plans to launch trials to study the agent in biomarker-defined cancer types, including breast and lung cancers.

The agency's decision not to approve this formulation was based on issues identified during a pre-approval inspection at a manufacturing facility, the firm said.

The firms have teamed up on a Phase I trial to evaluate the off-the-shelf cell therapy SN301A in patients with advanced GPC3-expressing liver cancers.

Under the terms of the agreement announced Wednesday, the Gates Foundation will invest up to $50 million to support the program's advancement into clinical testing. Tessera has said one of its goals ...

Scipher will contribute data derived from its PrismRA blood test to the Atropos Evidence Network, which underpins software tools, including an AI chatbot.